In other recent news, Viridian Therapeutics has announced a new $300 million sales agreement with Jefferies LLC, aimed at advancing the clinical development of its product candidates and preparing for commercialization. This agreement replaces a previous arrangement, allowing Viridian to sell shares over time at market prices. RBC Capital Markets has increased its price target for Viridian to $47.00, maintaining an Outperform rating, following positive results from the THRIVE-2 study for veligrotug in treating thyroid eye disease. The study showed significant improvement in proptosis and diplopia, setting veligrotug apart from competitors like Amgen (NASDAQ: AMGN )'s Tepezza.